After Hours Gainers:
Companies trading higher in after hours in reaction to earnings: RXDX +26.3%, FRSH +18.4%, ZQK +17.7%, WIX +9.3%, AEZS +7.4%, ENTL +4.2%, BONE +3.5%, CPXX +2.9%, ORCL +1.7%, NVGS +1.6%, MCUR +0.8%, WG +0.7%, EVOL +0.1%
Companies trading higher in after hours in reaction to news: VRML +30.1% (entered into three agreements with Quest Diagnostics (DGX): a global settlement agreement and mutual release, a testing and services agreement, and a non-exclusive license agreement), RXDX +26.3% (co and Teva Pharmaceuticals (TEVA) announced acquisition by Ignyta of four oncology R&D assets from Teva in exchange for 1.5 mln shares (6%) of Ignyta's common stock; RXDX also reported earnings), AKRX +5.5% (announced filing of 10-K for year ended December 31, 2014; in addition to second and third quarter 2014 financial statements), NETE +5.2% (co confirmed it will acquire PayOnline), HLF +4.5% (seeing reports that co has received a favorable court ruling), CIM +1.6% (announced that the Board has approved a reverse stock split of Chimera's outstanding shares of common stock at a ratio of 1-for-5; increased quarterly dividend to $0.096/share from $0.09/share),
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: FPRX -7.2%, ADBE -4%, OXGN -2.9%, EKSO -1.5%
Companies trading lower in after hours in reaction to news: NKTR -15.0% (announced Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer did not meet its primary and secondary endpoints), ANTH -8.0% (announced proposed public offering of common stock; size and price details not disclosed), RSPP -4.0% (announced the commencement of an underwritten public offering of 5 mln shares of its common stock by the Company and 4 mln shares of its common stock by certain selling stockholders), ESPR -3.0% (announced $150 mln offering of common stock), APP -2.6% (filed to delay FY14 Form 10-K due to ongoing discussions with Standard General regarding revolving credit facility), ESI -2.5% (filed to delay FY14 Form 10-K), BBX -2.1% (issued statement Regarding BFC Financial Corporation announcement of cash tender offer for shares of BBX Capital Class A Common Stock; Special Committee expects to retain a financial advisor and has retained Hogan Lovells US LLP as its legal advisor), CRR -1.6% (cut quarterly dividend by 70% to $0.10/share from $0.33/share)
The stock market ended the Tuesday session on a mixed note ahead of Wednesday's release of the latest policy directive from the Federal Reserve. The Nasdaq Composite added 0.2% while the S&P 500 and Dow Jones Industrial Average lost 0.3% and 0.7%, respectively.
Equity indices endured some selling in the early going, but the Nasdaq spent the day ahead of the broader market thanks to relative strength in the technology sector (+0.1%). Specifically, shares of Apple (AAPL 127.04, +2.09) climbed 1.7%, which underpinned the sector and the Nasdaq. Meanwhile, most large cap components struggled, which was also the case with high-beta chipmakers. The PHLX Semiconductor Index fell 0.7%. That being said, the daylong strength within the technology sector helped the broader market erase the bulk of its early decline.
The Nasdaq received another measure of support from biotechnology with the iShares Nasdaq Biotechnology ETF (IBB 356.25, +2.28) climbing 0.6% to a new record. However, the health care sector (-0.3%) could not turn positive.
Similarly, another influential sector—industrials (-0.4%)—ended in the red even though transport stocks displayed relative strength with the Dow Jones Transportation Average ending just below its flat line. The broader sector could not follow suit as the largest component—General Electric (GE 25.31, -0.14)—lost 0.6%.
Elsewhere among cyclical sectors, energy (-0.5%) settled among the laggards as crude oil faced continued pressure. The energy component fell 1.2% to $43.15/bbl after marking a session low at $42.75/bbl this morning. Crude oil endured a volatile day and made a brief appearance in the green while the Dollar Index (99.66, +0.06) spent the session near its unchanged level. However, the Dollar Index is likely to be active tomorrow when investors respond to the FOMC policy statement.
The main point of focus will be whether the Fed decides to keep its reference to remaining "patient" ahead of the first rate hike. In a recent appearance before the Senate Banking Committee, Fed Chair Janet Yellen said that removing the call for patience would open the door to a potential rate hike at any policy meeting that follows.
Treasuries held solid gains in the morning, but the 10-yr note cut its gain in half, sending the benchmark yield lower by two basis points to 2.06%.
Today's participation was below average with roughly 700 million shares changing hands at the NYSE floor.
Economic data was limited to February housing starts, which declined 17.0% to 897,000 from an upwardly revised 1.081 million (from 1.065 million) while the consensus expected a decline to 1.041 million. Record snowfall in the Northeast and extreme cold in the Midwest likely played a large part in curtailing new construction. Housing starts in these regions declined 45.0% in February, from 262,000 in January to 144,000. Those regions accounted for 64.0% of the entire February decline in housing starts.
Still, the weather can't be completely at fault. Poor underlying economic conditions likely caused some of the February pullback. For example, in the West region, warmer-than-normal temperatures should have helped offset some of the decline from the East, but that did not happen. Starts fell 18.2% to 239,000 in February from 292,000.
Tomorrow, the weekly MBA Mortgage Index will be released at 7:00 ET while the Federal Open Market Committee will release its latest policy statement at 14:00 ET.
- Nasdaq Composite +4.3% YTD
- Russell 2000 +3.2% YTD
- S&P 500 +0.7% YTD
- Dow Jones Industrial Average +0.2% YTD
FOMC Street Views:
* Barc: Patient removed. See risks are skewed towards the Fed’s revising its growth forecasts lower. Look for potential downward revision to inflation and growth forecasts. They expect lower inflation to likely to weigh on the expected path of the hiking cycle, even as the phrase “patient” is removed. They highlight this was the case between Sept/Dec ’14 as inflation f/cs weakened, despite lower u/e f/cs. In addition, look for Yellen is to emphasize that while the trajectory of the hiking cycle is data dependent, it should be very gradual, given the subdued inflation outlook and sluggish wage growth.
* CS: Expect next week's FOMC to see the "patient" wording removed. They note the dots are the obvious measure that has long been in focus, but the market continues to doubt the dots. Even the dots imply (by their calculations) only two hikes this year. The market remains unwilling to believe that the six hikes in 2016 that the dots currently imply can be realized. They are of the opinion that a few more strong data prints will help to reprice the market’s expectations for Fed action.
* DB: Looks for Fed to alter its forward guidance language to allow the Committee the flexibility to raise interest rates sometime around the middle of this year, possibly in June. This could mean removing "patient" from the meeting statement. Projections should indicate a more confident outlook for the labor market, although this will likely coincide with more tepid near-term inflation forecasts. GS: Fed to recognize the improvement in labour market conditions. Look for Fed to drop patience, replace with language suggesting increase in rates could be warranted if the committee is “reasonably confident” that inflation will move back over the medium term towards 2%. They recognize that a June hike is in play, but not a foregone conclusion. In SEPs; look for growth to be revised lower, inflation will be marked down substantially for 2015 & slightly for 2016, dots to come lower for end-of 2015 to 50-75bp range.
* HSBC: Fed drops "patient" reference. Future guidance on possible changes in the federal funds rate is now likely to focus on the state of the economy. They suggest the Committee may look to emphasize that it wants to be "reasonably confident" that inflation will return to 2% before it commences policy normalization. Some of the projections for the appropriate federal funds rate (in the "dot" diagram) might be lowered for 2015, given the reaction to the recent decline in inflation. They expect the Committee to wait until September before taking action.
* JPM: Fed drop "patient" replace it with more data-dependent guidance, stating need "reasonable confidence" in inflation returning to 2% before liftoff. Look for eco f/cs to be projected modestly lower; GDP, inflation, and unemployment, relative to the December f/c. Anticipate the "dots" to be revised somewhat lower as well, particularly for 2015. Yellen's will emphasize; (1) dropping "patient" means June is the earliest lift-off under consideration but that it could come later, and (2) the pace of rate hikes is more consequential than the exact timing of liftoff & it won't necessarily be "measured"—as per the 2004-2006 cycle—but could instead feature pauses between hikes, as conditions dictate.
* MS: Expect “patient” to be dropped. Committee may add that it will look to normalize policy once it feels “reasonably confident” it is appropriate to do so. Committee to remain concerned about international developments given the unrelenting ascent of the US dollar and its implications for growth, inflation, and financial conditions. Expect downward revisions to inflation – both headline and core – as well as the longer-run unemployment. Look for little change to the outlook for growth.
* Soc Gen: Fed to drop the word “patient” in the upcoming FOMC meeting next week but simultaneously lower its near-term forecasts for rates. Their economists expect the Fed to hike rates in June and only one more rate hike by year-end. In terms of market pricing vs. dots, they look for one-third of the gap to be closed by revisions to the FOMC “dots” and the remaining two-thirds by the market. See end of 2015
2015-03-17 18:16:33.383 GMT
By Hui-yong Yu
(Bloomberg) -- Blackstone Group LP, the world’s largest
private-equity investor in real estate, is unlikely to lead a
takeover offer for Macerich Co., according to a person with
knowledge of the firm’s thinking.
Macerich, the third-biggest publicly traded U.S. mall
owner, earlier Tuesday rejected a $16 billion takeover offer
from Simon Property Group Inc., the largest company in the
industry. REIT Zone, a newsletter, reported last week that
Blackstone may be working with other investors to put together a
group bid for the Santa Monica, California-based real estate
investment trust.
Blackstone hasn’t held talks to organize a competing
proposal and is unlikely to lead a future bid for Macerich, said
the person with knowledge of the matter, who asked not to be
named because the matter is private. The situation remains
fluid, the person said.
Peter Rose, a Blackstone spokesman, declined to comment.
Blackstone had invested with partners in 2010 to bring
General Growth Properties Inc., the No. 2 mall owner, out of
bankruptcy. It sold its shares at a profit three years later.
The New York-based firm also has been expanding in high-quality,
well-leased real estate through a new fund to acquire so-called
core-plus properties.
For Related News and Information:
Macerich Rejects Simon Property’s Bid to Acquire Mall Owner
Blackstone to Buy Chicago’s Willis Tower for $1.3 Billion
Simon’s Pursuit of Macerich Shows Allure of Top-Tier U.S. Malls
Top real estate stories: TOPR <GO>
Merger monitor: MA <GO>
To contact the reporter on this story:
Hui-yong Yu in Seattle at +1-206-262-4146 or
hyu@bloomberg.net
To contact the editors responsible for this story:
Kara Wetzel at +1-415-617-7318 or
kwetzel@bloomberg.net
Christine Maurus